![]() ![]() Coric spearheaded the acquisition of Biohaven by Pfizer in May 2022 for approximately $13 billion in total consideration.ĭr. Capitalizing on the extraordinary patient and shareholder value that Biohaven has built with Nurtec ODT and its CGRP franchise, Dr. Under his leadership, the company also filed an NDA for its second drug candidate, zavegepant, as the first intranasal CGRP antagonist for ultra-rapid relief of migraine. Biohaven also received approval in Europe and other major markets - advancing its “treat and prevent” migraine therapy to the approximately one billion patients suffering from migraine across the world. A little more than one year later, Biohaven transformed the migraine treatment paradigm with the FDA approval of an expanded indication for Nurtec ODT for the preventive treatment of episodic migraine - becoming the first all-in-one migraine medication for the acute and preventive treatment of migraine. Coric successfully led the company through its first FDA approval and the launch of Nurtec® ODT (rimegepant CGRP receptor antagonist) for the acute treatment of migraine. His leadership translated into dramatic growth for the company, from its initial pre-money valuation of about $6M to the sale of the company for $13B in total considerations. Coric led the company in the pursuit of its bold vision from an entrepreneurial start-up into a modern, publicly traded company listed on the New York Stock Exchange with the mission of advancing novel medications to underserved patients. ![]() ![]() In his over seven years as CEO of Biohaven, Dr. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |